The European LeukemiaNet: achievements and perspectives

The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

[1]  黄亚明（整理）,et al.  ICMJE , 2012 .

[2]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Barbui,et al.  JAK2V617F Mutation Persists IN Blasts and Mature CELLS of Transformed- JAK2V617F-POSITIVE-MYELOPROLIFERATIVE Neoplasia: A European LEUKEMIA NET (ENL) STUDY , 2010 .

[4]  T. Barbui,et al.  Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. , 2010, Blood.

[5]  S. Shurtleff,et al.  Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Barbui,et al.  JAK2V617F mutation persists in blasts and mature cells of transformedJAK2V617F‐positive‐myeloproliferative neoplasia: A European leukemia net (ENL) study , 2010, American journal of hematology.

[7]  Martin C. Müller,et al.  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.

[8]  M. Griesshammer,et al.  A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process , 2010, British journal of haematology.

[9]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[10]  Jean Feuillard,et al.  Four‐ and five‐color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL , 2009, Cytometry. Part B, Clinical cytometry.

[11]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. V. D. van der Velden,et al.  Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Brand,et al.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.

[14]  N. Cross,et al.  Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.

[15]  H. Kantarjian,et al.  Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase , 2009, Cancer.

[16]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[18]  M. Béné,et al.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet , 2009, Haematologica.

[19]  M. Griesshammer,et al.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. , 2009, Blood.

[20]  Giovanni Martinelli,et al.  Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.

[21]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[22]  A. Jones,et al.  Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions , 2009, Leukemia.

[23]  E. Estey,et al.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.

[24]  W. Hiddemann,et al.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Rezvani,et al.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.

[26]  Torsten Haferlach,et al.  An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase , 2008, British journal of haematology.

[27]  H. Einsele,et al.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.

[28]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[29]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[30]  L. Leibovici,et al.  Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients , 2007 .

[31]  C. Lass‐Flörl,et al.  Primary antifungal prophylaxis in leukaemia patients , 2007 .

[32]  T. Calandra,et al.  Empirical antifungal therapy in neutropaenic cancer patients with persistent fever , 2007 .

[33]  A. Thiébaut,et al.  Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients , 2007 .

[34]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[35]  B. Johansson,et al.  Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes , 2007, Genes, chromosomes & cancer.

[36]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[37]  K. Stamatopoulos,et al.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.

[38]  E. Kimby,et al.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.

[39]  J. Moake,et al.  Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. , 2007, Haematologica.

[40]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[41]  J. Goldman,et al.  Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia , 2006, Leukemia.

[42]  T Haferlach,et al.  Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks , 2006, Leukemia.

[43]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[44]  J. Sierra,et al.  The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. , 2006, Haematologica.

[45]  H. Einsele,et al.  Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT , 2005, Bone Marrow Transplantation.

[46]  W. Hiddemann,et al.  The German competence network ‘Acute and chronic leukemias’ , 2004, Leukemia.